Analysis of miRNA Expression in Patients with Rheumatoid Arthritis during Olokizumab Treatment

Bure, Irina V.; Mikhaylenko, Dmitry S.; Kuznetsova, Ekaterina; Алексеева, Е. А.; Bondareva, Kristina I.; Калинкин, А.И.; Lukashev, Alexander N.; Tarasov, Vadim V.; Zamyatnin, Andrey A.; Nemtsova, Marina V.

doi:10.3390/jpm10040205

Cited by 7 publications

(4 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…268 Furthermore, baseline plasma levels of miR-26b, miR-29, miR-451, and miR-522 in RA patients appear to be predictors of response to OKZ therapy, although the findings were derived from a Russian population. 269 MiRNA-BASED THERAPEUTIC STRATEGIES FOR RA Modern therapies for RA aim to achieve remission or at least low disease activity within 6 months, which is fulfilled by a treat-to-target strategy that involves rigorous disease control and individualized management. 270 To date, the first-line medication for RA patients has been cDMARDs, primarily MTX, supplemented with glucocorticoids and/or nonsteroidal anti-inflammatory drugs.…”

Section: Contribution To Prevention and Precise Diagnosismentioning

confidence: 99%

Comprehensive overview of microRNA function in rheumatoid arthritis

Peng

Wang

et al. 2023

Bone Res

View full text Add to dashboard Cite

MicroRNAs (miRNAs), a class of endogenous single-stranded short noncoding RNAs, have emerged as vital epigenetic regulators of both pathological and physiological processes in animals. They direct fundamental cellular pathways and processes by fine-tuning the expression of multiple genes at the posttranscriptional level. Growing evidence suggests that miRNAs are implicated in the onset and development of rheumatoid arthritis (RA). RA is a chronic inflammatory disease that mainly affects synovial joints. This common autoimmune disorder is characterized by a complex and multifaceted pathogenesis, and its morbidity, disability and mortality rates remain consistently high. More in-depth insights into the underlying mechanisms of RA are required to address unmet clinical needs and optimize treatment. Herein, we comprehensively review the deregulated miRNAs and impaired cellular functions in RA to shed light on several aspects of RA pathogenesis, with a focus on excessive inflammation, synovial hyperplasia and progressive joint damage. This review also provides promising targets for innovative therapies of RA. In addition, we discuss the regulatory roles and clinical potential of extracellular miRNAs in RA, highlighting their prospective applications as diagnostic and predictive biomarkers.

show abstract

Section: Contribution To Prevention and Precise Diagnosismentioning

confidence: 99%

Comprehensive overview of microRNA function in rheumatoid arthritis

Peng

Wang

et al. 2023

Bone Res

View full text Add to dashboard Cite

show abstract

“…MTX has been shown to cause increased marrow adiposity and reduced trabecular bone volume; it has been reported that MTX upregulates miR-6315 after treatment, which might be a vital cause of bone and marrow fat formation [138]. Similarly, statistically significant differences between miR-26b, miR-29, miR-451, and miR-522 were observed after olokizumab therapy [139].…”

Section: Micro Rnamentioning

confidence: 99%

New Targets and Strategies for Rheumatoid Arthritis: From Signal Transduction to Epigenetic Aspect

et al. 2023

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic autoimmune disease that can lead to joint damage and even permanent disability, seriously affecting patients’ quality of life. At present, the complete cure for RA is not achievable, only to relieve the symptoms to reduce the pain of patients. Factors such as environment, genes, and sex can induce RA. Presently, non-steroidal anti-inflammatory drugs, DRMADs, and glucocorticoids are commonly used in treating RA. In recent years, some biological agents have also been applied in clinical practice, but most have side effects. Therefore, finding new mechanisms and targets for treating RA is necessary. This review summarizes some potential targets discovered from the perspective of epigenetics and RA mechanisms.

show abstract

“…lnc-ITSN1-2 could be a convincing biomarker for RA diagnosis and monitoring of disease activity as it is significantly upregulated in the plasma and synovial tissues of RA patients and positively correlated with DAS28, ESR, and CRP. Notably, the ROC curve analysis showed that lnc-ITSN1-2 had good diagnostic value (AUC = 0.898, specificity = 80%, and sensitivity = 90%) ( 145 , 146 ).…”

Section: Candidate Rnas As Biomarkers For Ramentioning

confidence: 99%

Biomarkers (mRNAs and non-coding RNAs) for the diagnosis and prognosis of rheumatoid arthritis

Jiang

Zhong

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

In recent years, diagnostic and therapeutic approaches for rheumatoid arthritis (RA) have continued to improve. However, in the advanced stages of the disease, patients are unable to achieve long-term clinical remission and often suffer from systemic multi-organ damage and severe complications. Patients with RA usually have no overt clinical manifestations in the early stages, and by the time a definitive diagnosis is made, the disease is already at an advanced stage. RA is diagnosed clinically and with laboratory tests, including the blood markers C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) and the autoantibodies rheumatoid factor (RF) and anticitrullinated protein antibodies (ACPA). However, the presence of RF and ACPA autoantibodies is associated with aggravated disease, joint damage, and increased mortality, and these autoantibodies have low specificity and sensitivity. The etiology of RA is unknown, with the pathogenesis involving multiple factors and clinical heterogeneity. The early diagnosis, subtype classification, and prognosis of RA remain challenging, and studies to develop minimally invasive or non-invasive biomarkers in the form of biofluid biopsies are becoming more common. Non-coding RNA (ncRNA) molecules are composed of long non-coding RNAs, small nucleolar RNAs, microRNAs, and circular RNAs, which play an essential role in disease onset and progression and can be used in the early diagnosis and prognosis of RA. In this review of the diagnostic and prognostic approaches to RA disease, we provide an overview of the current knowledge on the subject, focusing on recent advances in mRNA–ncRNA as diagnostic and prognostic biomarkers from the biofluid to the tissue level.

show abstract

Analysis of miRNA Expression in Patients with Rheumatoid Arthritis during Olokizumab Treatment

Cited by 7 publications

References 40 publications

Comprehensive overview of microRNA function in rheumatoid arthritis

Comprehensive overview of microRNA function in rheumatoid arthritis

New Targets and Strategies for Rheumatoid Arthritis: From Signal Transduction to Epigenetic Aspect

Biomarkers (mRNAs and non-coding RNAs) for the diagnosis and prognosis of rheumatoid arthritis

Contact Info

Product

Resources

About